Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

2 weeks ago

Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial …

Read Entire Article

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Related

Bipartisan Support Grows for Key Crypto Issues in the U.S.

Tether’s $5B mint and political entanglements raise suspicio...

Critics Debate Microstrategy’s High-Stakes Bitcoin Play: Gen...

IS SATOSHI NAKAMOTO CASHING OUT?

Gensler’s SEC made US ‘nearly untenable’ for crypto firms, s...

Pantera Bitcoin Fund Achieves 1,000x Milestone Amidst Market...

Is Crypto All-Stars The Next Binance Listing? New Meme Coin ...

Is It Time to Buy Pepe Coin After a 10% Drop or Move to Pepe...

Popular

Dogecoin Vs. PEPE: Analyst Reveals Which Coin You Should Hol...

Following the Money in Markets

Michael Saylor Pushes Strategic Bitcoin Reserve Citing Ameri...

Trump Family Crypto Project World Liberty Financial Gets a $...

Ethereum and Meme Coins in the White House? Trump’s $5.43M C...

OPI Shares Surge Over 44% As Debt Refinancing Plan Offers $3...